TW523511B - Pharmaceutical composition comprising substituted imidazole compounds and process for preparing compounds - Google Patents

Pharmaceutical composition comprising substituted imidazole compounds and process for preparing compounds Download PDF

Info

Publication number
TW523511B
TW523511B TW085103208A TW85103208A TW523511B TW 523511 B TW523511 B TW 523511B TW 085103208 A TW085103208 A TW 085103208A TW 85103208 A TW85103208 A TW 85103208A TW 523511 B TW523511 B TW 523511B
Authority
TW
Taiwan
Prior art keywords
alkyl
formula
scope
patent application
item
Prior art date
Application number
TW085103208A
Other languages
English (en)
Chinese (zh)
Inventor
Jerry Leroy Adams
Timothy F Gallagher
Ravi Shanker Garigipati
Jeffrey Charles Boehm
Joseph Sisko
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of TW523511B publication Critical patent/TW523511B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
TW085103208A 1995-01-09 1996-03-18 Pharmaceutical composition comprising substituted imidazole compounds and process for preparing compounds TW523511B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36996495A 1995-01-09 1995-01-09
US08/472,366 US5593992A (en) 1993-07-16 1995-06-07 Compounds

Publications (1)

Publication Number Publication Date
TW523511B true TW523511B (en) 2003-03-11

Family

ID=27004764

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085103208A TW523511B (en) 1995-01-09 1996-03-18 Pharmaceutical composition comprising substituted imidazole compounds and process for preparing compounds

Country Status (33)

Country Link
US (5) US5593992A (en, 2012)
EP (2) EP1264827A1 (en, 2012)
JP (2) JP3330952B2 (en, 2012)
CN (1) CN1138546C (en, 2012)
AP (1) AP1270A (en, 2012)
AR (1) AR002267A1 (en, 2012)
AT (1) ATE254613T1 (en, 2012)
AU (1) AU705207C (en, 2012)
BG (1) BG63769B1 (en, 2012)
BR (1) BR9606904A (en, 2012)
CA (1) CA2209938A1 (en, 2012)
CZ (1) CZ215897A3 (en, 2012)
DE (1) DE69630777T2 (en, 2012)
DK (1) DK0809499T3 (en, 2012)
DZ (1) DZ1961A1 (en, 2012)
ES (1) ES2210348T3 (en, 2012)
FI (1) FI972901L (en, 2012)
HU (1) HUP9702409A3 (en, 2012)
ID (3) ID23597A (en, 2012)
IL (7) IL134324A (en, 2012)
IN (3) IN184957B (en, 2012)
MA (1) MA23770A1 (en, 2012)
MX (1) MX9705142A (en, 2012)
NO (3) NO973167L (en, 2012)
NZ (1) NZ301204A (en, 2012)
OA (1) OA10738A (en, 2012)
PL (1) PL322249A1 (en, 2012)
PT (1) PT809499E (en, 2012)
RU (2) RU2196139C2 (en, 2012)
SI (1) SI0809499T1 (en, 2012)
SK (1) SK90297A3 (en, 2012)
TW (1) TW523511B (en, 2012)
WO (1) WO1996021452A1 (en, 2012)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
DE69421624T2 (de) * 1993-09-17 2000-07-20 Smithkline Beecham Corp., Philadelphia Medikamente bindendes protein
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
EP0802908A4 (en) * 1995-01-12 2001-04-11 Smithkline Beecham Corp NEW CONNECTIONS
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
TR199801361T2 (xx) * 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
WO1997032583A1 (en) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
CA2271767A1 (en) 1996-11-19 1998-05-28 Nathan B. Mantlo Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
AP999A (en) * 1997-01-10 2001-08-11 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1000055A1 (en) * 1997-05-22 2000-05-17 G.D. Searle & Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
EP0983260A2 (en) * 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
ES2270520T3 (es) 1997-06-12 2007-04-01 Aventis Pharma Limited Imidazolil-acetales ciclicos.
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
JP2002515915A (ja) * 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 炎症性疾患の治療で有用な２−置換イミダゾール類
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
JP2002509537A (ja) 1997-07-02 2002-03-26 スミスクライン・ビーチャム・コーポレイション 新規なシクロアルキル置換イミダゾール化合物
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
JP2001519381A (ja) * 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのｃｓａｉｄｔｍ化合物の使用
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
CA2314980A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
WO1999061440A1 (en) * 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
WO2000025791A1 (en) * 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6469018B1 (en) 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
EP1185528A4 (en) * 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
ES2241675T3 (es) 1999-11-23 2005-11-01 Smithkline Beecham Corporation Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa.
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
PT1175214E (pt) * 1999-12-08 2005-04-29 Pharmacia Corp Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP2004503601A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
NZ524252A (en) * 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
WO2002059083A2 (en) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ATE377598T1 (de) 2001-01-22 2007-11-15 Sankyo Co Durch bicyclische aminogruppen substituierte verbindungen
CN1781903A (zh) 2001-03-26 2006-06-07 奥索-麦克尼尔药品公司 制备四取代咪唑衍生物及其新型晶体结构的方法
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
TWI329642B (en) * 2001-10-22 2010-09-01 Mitsubishi Tanabe Pharma Corp 4-imidazolin-2-one compounds
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
CA2497240A1 (en) 2002-08-29 2004-03-11 Andrew Asher Protter Methods of promoting osteogenesis
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
DE60334016D1 (de) 2002-11-05 2010-10-14 Glaxo Group Ltd Antibakterielle mittel
ES2335279T3 (es) * 2002-12-16 2010-03-24 Astrazeneca Uk Limited Procedimiento para la preparacion de compuestos de pirimidina.
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
EP1692111A2 (en) * 2003-12-12 2006-08-23 Wyeth, A Corporation of the State of Delaware Quinolines useful in treating cardiovascular disease
RU2006121487A (ru) * 2003-12-18 2007-12-27 Пфайзер Продактс Инк. (Us) СПОСОБЫ ЛЕЧЕНИЯ ОСТРОГО ВОСПАЛЕНИЯ У ЖИВОТНЫХ С ПОМОЩЬЮ ИНГИБИТОРОВ р38 МАР-киназы
AR049511A1 (es) * 2004-06-10 2006-08-09 Irm Llc Compuestos y composiciones como inhibidores de quinasa de proteina
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CN101010421B (zh) * 2004-08-31 2011-08-03 三洋化成工业株式会社 表面活性剂
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
JP2008537937A (ja) * 2005-03-25 2008-10-02 グラクソ グループ リミテッド ピリド［２，３−ｄ］ピリミジン−７−オンおよび３，４−ジヒドロピリミド［４，５−ｄ］ピリミジン−２（１Ｈ）−オン誘導体の製造方法
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
EP1871770A1 (en) * 2005-04-22 2008-01-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
MX2008013530A (es) 2006-04-20 2009-01-14 Janssen Pharmaceutica Nv Inhibidores de c-fms cinasa.
NZ572073A (en) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocyclic compounds as inhibitors of c-fms kinase
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
CN101821393A (zh) * 2007-06-05 2010-09-01 美国西联生物制药公司 诱导t细胞细胞因子的表面分子和使用方法
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CN102573906B (zh) * 2009-02-06 2015-02-11 四川汇宇制药有限公司 抑免蛋白/亲环蛋白和emmprin免疫球蛋白受体超家族成员的双重抑制
RU2418582C1 (ru) * 2010-04-08 2011-05-20 Аверин Константин Михайлович 1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
KR20150042834A (ko) * 2012-08-16 2015-04-21 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피라졸
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104496906B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种咪唑的制备方法
CN104402823B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种1，2-二甲基咪唑的制备方法
EP3273955A4 (en) 2015-03-23 2019-05-01 The University of Melbourne TREATMENT OF RESPIRATORY DISEASES
WO2018201192A1 (en) * 2017-05-03 2018-11-08 The University Of Melbourne Compounds for the treatment of respiratory diseases
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2020093097A1 (en) * 2018-11-07 2020-05-14 The University Of Melbourne Compounds and compositions for the treatment of respiratory diseases
EP3725768A1 (en) 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole
EP4410989A3 (en) 2019-08-23 2024-12-11 Mochida Pharmaceutical Co., Ltd. Method for producing heterocyclidene acetamide derivatives

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE34580B1 (en) * 1969-03-11 1975-06-25 Glaxo Lab Ltd Improvements in or relating to cephalosporin compounds
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
EP0004648B1 (de) * 1978-04-11 1982-08-25 Ciba-Geigy Ag Neue Mercaptoimidazolderivate, Verfahren zu deren Herstellung, Mercaptoimidazolderivate zur Behandlung entzündlicher Erkrankungen und diese enthaltende pharmazeutische Präparate
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (en, 2012) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IE59893B1 (en) * 1986-04-16 1994-04-20 Roussel Uclaf Process for the manufacture of n-(sulfonylmethyl) formamides
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
US5166400A (en) * 1989-01-19 1992-11-24 Pfizer Inc. Intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates
CA2098177A1 (en) * 1990-12-13 1992-06-13 Jerry L. Adams Csaids
IE914327A1 (en) * 1990-12-13 1992-06-17 Smithkline Beecham Corp Novel csaids
EP0624159B1 (en) * 1992-01-13 1998-11-25 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
IL114483A0 (en) * 1994-07-12 1995-11-27 Yissum Res Dev Co Glycinamide derivatives pharmaceutical compositions containing the same and methods utilizing the same
EP0802908A4 (en) * 1995-01-12 2001-04-11 Smithkline Beecham Corp NEW CONNECTIONS

Also Published As

Publication number Publication date
SI0809499T1 (en) 2004-04-30
NO20016226D0 (no) 2001-12-19
DE69630777T2 (de) 2004-07-29
AU705207B2 (en) 1999-05-20
IL134324A (en) 2001-08-26
SK90297A3 (en) 1998-01-14
IL134324A0 (en) 2001-04-30
EP0809499A1 (en) 1997-12-03
BG63769B1 (bg) 2002-12-29
DK0809499T3 (da) 2004-03-29
IL134322A0 (en) 2001-04-30
CZ215897A3 (cs) 1998-04-15
NO973167D0 (no) 1997-07-08
IL134323A (en) 2001-11-25
ID23597A (id) 1996-10-10
IN188338B (en, 2012) 2002-09-07
IL134322A (en) 2001-09-13
HUP9702409A2 (hu) 1999-05-28
AP9701021A0 (en) 1997-07-31
NO20016225D0 (no) 2001-12-19
IL134323A0 (en) 2001-04-30
US20020188122A1 (en) 2002-12-12
ES2210348T3 (es) 2004-07-01
AU4657296A (en) 1996-07-31
US6222036B1 (en) 2001-04-24
IL116455A (en) 2001-07-24
NO20016225L (no) 1997-09-08
ID23273A (id) 1996-10-10
IN188339B (en, 2012) 2002-09-07
IL116455A0 (en) 1996-03-31
EP1264827A1 (en) 2002-12-11
BG101727A (bg) 1998-03-31
ATE254613T1 (de) 2003-12-15
RU2196139C2 (ru) 2003-01-10
OA10738A (en) 2002-12-11
ID23599A (id) 1996-10-10
CA2209938A1 (en) 1996-07-18
EP0809499B1 (en) 2003-11-19
HUP9702409A3 (en) 1999-06-28
US6103936A (en) 2000-08-15
BR9606904A (pt) 1997-10-21
MX9705142A (es) 1997-10-31
PL322249A1 (en) 1998-01-19
NZ301204A (en) 1999-05-28
PT809499E (pt) 2004-04-30
RU2002122174A (ru) 2004-02-27
JP2002105047A (ja) 2002-04-10
MA23770A1 (fr) 1996-10-01
US5663334A (en) 1997-09-02
JP3330952B2 (ja) 2002-10-07
HK1003623A1 (en) 1999-02-12
FI972901A0 (fi) 1997-07-08
DZ1961A1 (fr) 2002-02-17
NO20016226L (no) 1997-09-08
AP1270A (en) 2004-04-16
JPH10512555A (ja) 1998-12-02
DE69630777D1 (de) 2003-12-24
CN1177299A (zh) 1998-03-25
CN1138546C (zh) 2004-02-18
FI972901A7 (fi) 1997-09-08
AR002267A1 (es) 1998-03-11
US5593992A (en) 1997-01-14
EP0809499A4 (en) 1998-10-14
IN184957B (en, 2012) 2000-10-07
AU705207C (en) 2002-09-19
NO973167L (no) 1997-09-08
WO1996021452A1 (en) 1996-07-18
FI972901L (fi) 1997-09-08

Similar Documents

Publication Publication Date Title
TW523511B (en) Pharmaceutical composition comprising substituted imidazole compounds and process for preparing compounds
TW442481B (en) Imidazole compounds having an action of inhibiting cytokine, a process for the preparation thereof, and a pharmaceutical composition comprising them
TW523512B (en) Novel substituted imidazole compounds
TW505637B (en) Novel substituted imidazole compounds
AU694130B2 (en) Tri-substituted imidazoles having multiple therapeutic properties
TW517055B (en) Novel substituted imidazole compounds
JP2023503052A (ja) Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
EP3889134B1 (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
CZ218198A3 (cs) Nové cykloalkylem substituované imidazoly, způsob jejich přípravy, farmaceutické prostředky s jejich obsahem a způsob inhibice
JPH10512264A (ja) 新規化合物
JP2002507994A (ja) 新規な置換イミダゾール化合物
JP2001508395A (ja) 新規シクロアルキル置換イミダゾール
EA024109B1 (ru) Ингибиторы протеинкиназ
WO2012149528A1 (en) Inhibitors of inducible form of 6-phosphofructose-2-kinase
KR100840816B1 (ko) ＴＮＦ-α시그널링의 조절물질
CN107922350A (zh) 新的苯并咪唑化合物及其医药用途
JP3527181B2 (ja) ピラゾール類
TW200812979A (en) Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200808762A (en) Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
AU2005311452A1 (en) Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine D3 receptor
HK40051501A (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
HK1052690A (en) Process for the preparation of tosylbenzylformamides
HK1135091B (zh) 三唑基苯基苯磺酰胺
HK1135091A1 (en) Triazolyl phenyl benzenesulfonamides

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees